On June 10, 2025 Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, reported Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics (Press release, Bonum Therapeutics, JUN 10, 2025, View Source [SID1234653809])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees.

Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit.

The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals.

Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company’s acquisition by Roche and the subsequent spinout of Bonum.

She will be joined by four panelists representing different perspectives on the technology’s potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics.

Alexandra Cantley, Ph.D., Partner, Polaris Partners
Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics
Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics
John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals
Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity